Entering text into the input field will update the search result below

Teva to relaunch generic version of injectable contraceptive Depo-Provera in U.S.

  • Teva Pharmaceutical Industries (NYSE:TEVA) reintroduces its generic equivalent to Depo-Provera Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL in the U.S. for the prevention of pregnancy.
  • The company says it is committed to strengthening its generic injectable business, beefing up investment in high-value products. It says it has almost 600 generic medicines available and over 100 pending first-to-file applications in the U.S.
  • The U.S. market is ~$211M.

Recommended For You

About TEVA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TEVA--
Teva Pharmaceutical Industries Limited